A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Phase 2
200
about 2.7 years
18+
8 sites in GA, MI, NJ +3
About this study
This trial is testing a treatment called raludotatug deruxtecan (R-DXd) for people with advanced or metastatic solid tumors. The goal is to see if R-DXd can help improve the lives of those who have these types of cancers.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Raludotatug deruxtecan
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Disease Control Rate (DCR) as Assessed by the Investigator (ccRCC Cohort Only), Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs) (All Cohorts), Objective Response Rate as Assessed by the Investigator (All Cohorts Except ccRCC)
Secondary: Disease Control Rate (DCR) as Assessed by the Investigator (All Cohorts Except ccRCC Cohort), Duration of Response (DoR) as Assessed by the Investigator, Objective Response Rate as Assessed by the Investigator (ccRCC Cohort Only), Pharmacokinetic Parameter Maximum Concentration (Cmax) of R-DXd, Progression-free Survival (PFS) as Assessed by the Investigator
Oncology